Alprostadil (Caverject/MUSE) Global Regulatory Status: FDA Approval, Label, and Safety

FDA Approval History and NDA Records

Alprostadil became one of the first pharmacologic treatments specifically approved for erectile dysfunction in the United States. Caverject (alprostadil for injection, Pfizer) received FDA approval in July 1995 under NDA 019677, and MUSE (alprostadil urogenital suppository, Meda Pharmaceuticals) followed in November 1996 under NDA 020527. Both approvals predated sildenafil by two to three years, making alprostadil the dominant office-based ED therapy through the late 1990s.

Caverject NDA 019677

The original Caverject NDA relied on key evidence that included the landmark Linet et al. Trial published in the New England Journal of Medicine in 1996, which enrolled 296 men with chronic erectile dysfunction 1. In that randomized, double-blind, placebo-controlled study, 94% of alprostadil-treated injections produced erections sufficient for intercourse compared with 8% under placebo. The FDA's review of that efficacy dataset, combined with a well-characterized adverse-event profile, supported the July 1995 approval.

Pfizer later received supplemental approvals for Caverject Impulse (a prefilled, dual-chamber syringe device) under the same NDA. Current labeling and approval documents are available through the FDA Drugs@FDA database.

MUSE NDA 020527

MUSE received approval for the intraurethral route, which was considered a less invasive delivery method. The approval package included data from a multicenter, randomized trial demonstrating that 65% of home-use attempts with alprostadil 500 mcg or 1,000 mcg led to intercourse, compared with 19% on placebo 2. Post-approval, the FDA has required labeling updates reflecting syncope risk and the need for an in-office trial dose before home use.

Generic Alprostadil Approvals

Multiple generic injectable alprostadil products have received FDA approval under the 505(j) Abbreviated New Drug Application pathway. The FDA's Orange Book lists therapeutically equivalent generics for both the 10 mcg/mL and 20 mcg/mL concentrations. Edex (alprostadil alfadex, Endo Pharmaceuticals) received its own NDA approval in December 1997, using a different formulation (alprostadil complexed with alpha-cyclodextrin) that allows reconstitution and storage differences from Caverject 3.

Current FDA-Approved Prescribing Label Requirements

The FDA label for both Caverject and MUSE governs indication, dosing, contraindications, warnings, and required patient counseling. Clinicians must follow the current label, which is periodically updated through the FDA's labeling revision process.

Approved Indication and Patient Population

Both products carry approval for erectile dysfunction in adult males. The label does not authorize use in women, pediatric patients, or neonates (despite a separate neonatal indication for IV alprostadil in congenital heart disease, which is a different formulation and NDA entirely). The prescribing information specifies that alprostadil is intended for men who have failed or cannot use oral phosphodiesterase-5 inhibitors, though this is not a required precondition under the label's indication text.

Dosing and Titration Requirements

The FDA label mandates in-office titration for Caverject before home use. The initial dose is 2.5 mcg; if the response is inadequate, the prescriber may increase to 5 mcg, then in increments of 5 to 10 mcg. The label defines the optimal dose as the lowest dose that produces an erection sufficient for intercourse and lasting no longer than 60 minutes. The maximum recommended dose is 60 mcg for neurogenic erectile dysfunction and 40 mcg for vasculogenic or psychogenic etiologies 4.

For MUSE, the label recommends starting at 125 to 250 mcg with the first dose administered in a medical office under observation for at least 30 minutes, because hypotension and syncope have been reported within 1 hour of administration 5.

Contraindications Listed in the Label

The current Caverject label lists these contraindications 6:

• Hypersensitivity to alprostadil
• Conditions predisposing to priapism, including sickle cell anemia or trait, multiple myeloma, and leukemia
• Anatomical deformity of the penis (e.g., angulation, cavernosal fibrosis, Peyronie's disease) severe enough to preclude safe injection
• Men for whom sexual activity is inadvisable due to cardiovascular status
• Concomitant use of penile implants
• Use in female partners who are pregnant unless a condom is used (due to prostaglandin effects on cervical tissue)

Boxed Warnings and Risk Evaluation

No boxed warning (Black Box Warning) appears on the current Caverject or MUSE prescribing information. However, both labels carry bolded Warnings and Precautions sections covering prolonged erection (defined as erection lasting 4 to 6 hours), priapism (erection lasting more than 6 hours), penile fibrosis with long-term use, and hypotension 7.

The label requires that patients be instructed to seek immediate medical attention for any erection lasting more than 4 hours. This instruction must appear in the patient package insert and the Medication Guide distributed at dispensing.

Post-Market Safety Surveillance and Pharmacovigilance

FDA MedWatch and Adverse Event Reporting

Since the original approvals in 1995 and 1996, FDA's MedWatch program has collected adverse event reports for both formulations. The most frequently reported serious events in the FDA Adverse Event Reporting System (FAERS) database include priapism, penile pain, and penile fibrosis. A subset of cases involved emergency department visits for priapism requiring aspiration or intracavernosal phenylephrine injection.

The FDA Sentinel System, which uses electronic health record and claims data from more than 100 million patients, continues to monitor alprostadil safety signals as part of routine post-market surveillance 8. No new safety signals have prompted label changes specific to priapism frequency since 2001, though the fibrosis warning has been reinforced in subsequent labeling revisions.

Penile Fibrosis Incidence from Clinical Studies

Long-term use of intracavernosal alprostadil carries a penile fibrosis risk that the label quantifies at approximately 3% of patients in clinical studies lasting up to 2 years 9. A prospective study by Porst et al. Tracking 449 men over 4 years found that 7.8% developed palpable plaques or fibrosis with regular intracavernosal injection therapy 10. Patients using more than 3 injections per week showed higher rates than those injecting once weekly.

Cardiovascular Safety Data

Alprostadil produces local vasodilation but can also cause systemic hypotension, particularly with MUSE. A post-marketing analysis published in the Journal of Urology found that 3.3% of MUSE users experienced dizziness or symptomatic hypotension requiring rest, and 0.4% experienced syncope during in-office observation 11. The prescribing label for MUSE requires that the first dose be administered in a medical setting for this reason.

The American Heart Association guidelines on sexual activity and cardiovascular disease note that PDE-5 inhibitors carry a drug interaction risk with nitrates that alprostadil does not share, making alprostadil a consideration for some patients on nitrate therapy, though the cardiovascular risk of the sexual activity itself must still be assessed 12.

European Regulatory Status

EMA and National Authorizations

Alprostadil is approved across multiple EU member states, primarily through national authorization procedures rather than a centralized EMA marketing authorization. In Germany, the United Kingdom (pre-Brexit), France, and Spain, alprostadil injection products hold marketing authorizations with labeling broadly consistent with the FDA's requirements. The EMA's EPAR (European Public Assessment Report) process applies only to centrally authorized products; alprostadil has historically been authorized at the national level, so no single EPAR covers all EU formulations.

UK MHRA Status

Following Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) maintains separate oversight. Caverject and MUSE both held UK marketing authorizations prior to Brexit and transitioned to MHRA jurisdiction under the Withdrawal Agreement. The MHRA's published product information aligns with the FDA label on key safety warnings, including the priapism and fibrosis precautions. Clinicians in the UK can access current summaries of product characteristics (SmPCs) through the MHRA's Yellow Card and product database.

EU Label Differences from FDA Label

Minor differences exist between EU SmPCs and the FDA prescribing information. EU labeling typically provides more detailed guidance on injection technique training requirements and places greater emphasis on partner counseling. The maximum intracavernosal dose in most EU SmPCs is 40 mcg regardless of etiology, compared with 60 mcg allowed by the FDA label for neurogenic cases. This discrepancy reflects different benefit-risk assessments at the time of approval and does not represent a safety finding from post-market data.

Regulatory Status in Canada and Australia

Health Canada

Health Canada approved alprostadil for injection (Caverject) under Drug Identification Number (DIN) listing in the mid-1990s. The Canadian product monograph mirrors the FDA label in its dosing titration requirements and contraindications. Health Canada's Drug Product Database lists multiple alprostadil products, and the agency has not issued market withdrawal notices or safety advisories specific to alprostadil beyond routine label update harmonization 13.

Therapeutic Goods Administration (Australia)

The Australian TGA granted registration to Caverject under the Australian Register of Therapeutic Goods (ARTG). The TGA's Product Information document requires the same in-office titration and priapism counseling as the FDA label. Australia does not have an approved MUSE equivalent listed on the ARTG as of the most recent public database review, though patients may access MUSE through the TGA's Special Access Scheme under Category B provisions for unapproved therapeutic goods.

Original Clinical Decision Framework: Selecting Alprostadil Formulation Based on Regulatory and Clinical Criteria

The choice between Caverject and MUSE involves both regulatory and clinical factors. The following framework integrates FDA label requirements with patient-specific variables.

Step 1. Confirm no contraindications exist. Review the full contraindication list from the current FDA prescribing information before any trial dose. Sickle cell disease, penile implant, and current pregnancy in the partner (without condom use) are absolute contraindications.

Step 2. Assess manual dexterity and injection comfort. Caverject requires self-injection technique training. Patients with limited hand strength, severe anxiety about needles, or visual impairment may prefer MUSE, accepting the lower efficacy rate (approximately 65% vs. 94% intercourse success in key trials) 1 2.

Step 3. Conduct the mandatory in-office first dose. The FDA label requires this for both formulations. Caverject titration starts at 2.5 mcg; MUSE observation requires 30 minutes minimum for hypotension screening.

Step 4. Establish a home-use dose and frequency ceiling. Document the titrated dose in the chart. Reinforce the 3-per-week maximum and the instruction to seek care for erections lasting more than 4 hours.

Step 5. Schedule a 3-month follow-up. Assess for penile pain, nodules, or curvature changes that may indicate early fibrosis. The 7.8% fibrosis rate at 4 years in chronic users 10 makes periodic palpation part of standard monitoring.

Clinician and Guideline Perspectives

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states directly: "Intracavernosal vasoactive drug administration (e.g., alprostadil, papaverine/phentolamine) should be offered to patients as a treatment option for ED" 14. The guideline assigns this a Moderate Recommendation based on Grade B evidence.

The International Society for Sexual Medicine (ISSM) echoes this position, noting that alprostadil monotherapy produces erections in 70 to 80% of unselected ED patients when properly titrated, and that combination intracavernosal therapy (adding papaverine and phentolamine, the "Trimix" formulation) may achieve higher rates in refractory cases, though Trimix lacks its own FDA approval and is dispensed as a compounded preparation 15.

The AUA guideline also specifies: "Clinicians should discuss the risk of priapism with patients initiating intracavernosal therapy and should provide clear written instructions on seeking emergency care," a requirement that aligns directly with FDA label language on patient counseling 14.

Compounded Alprostadil and Regulatory Considerations

FDA-approved Caverject and MUSE are distinct from compounded alprostadil preparations mixed by 503A and 503B pharmacies. Compounded alprostadil (including Trimix and Bimix formulations containing alprostadil) is not FDA-approved and does not carry the same NDA-based safety and efficacy database. The FDA has issued guidance on compounding clarifying that compounded products may not be marketed as equivalent to approved products and that compounding pharmacies must meet USP <797> sterility standards for injectable preparations 16.

Clinicians prescribing compounded alprostadil accept responsibility for the absence of FDA review of that specific formulation. Patients should be informed that compounded preparations have not undergone the same pre-market clinical trial review as Caverject or MUSE.

Pediatric and Neonatal Alprostadil: A Separate Regulatory Category

Alprostadil for pediatric use (Prostin VR Pediatric, alprostadil injection 500 mcg/mL) is an entirely separate NDA indicated for temporary maintenance of patent ductus arteriosus in neonates with congenital heart defects. This product, the dosing (0.05 to 0.1 mcg/kg/min IV infusion), and the safety profile are unrelated to Caverject or MUSE 17. Prescribers should not conflate the two regulatory categories. The neonatal indication is not discussed in the Caverject or MUSE prescribing information and vice versa.

Summary of Global Regulatory Approvals

| Jurisdiction | Product | Approval Status | Regulatory Body | |---|---|---|---| | United States | Caverject (NDA 019677) | Approved July 1995 | FDA CDER | | United States | MUSE (NDA 020527) | Approved November 1996 | FDA CDER | | United States | Edex (NDA 020547) | Approved December 1997 | FDA CDER | | European Union | Multiple national MAs | Approved, national level | National CAs | | United Kingdom | Caverject, MUSE | Approved (MHRA) | MHRA | | Canada | Caverject (DIN listed) | Approved | Health Canada | | Australia | Caverject (ARTG) | Approved | TGA | | Australia | MUSE | Not TGA-registered; SAS access | TGA |